{
  "ticker": "PYC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966520",
  "id": "02966520",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250707",
  "time": "0857",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljjclhf3ykwp.pdf",
  "summary": "- **Clinical Trial Progress:** PYC Therapeutics advancing to Part B of Single Ascending Dose (SAD) study for PYC-003 in Polycystic Kidney Disease (PKD) patients.  \n- **Dosing Escalation:** Cohort 3 dosing approved in Part A (healthy volunteers) after safety review.  \n- **Timeline:** PKD patient dosing to commence July 2025; repeat dose studies (MAD) planned for Q4 2025.  \n- **Milestone:** Safety/tolerability confirmed at efficacy-relevant dose, supporting pivotal study progression.  \n\n*No material capital markets or trading-specific information (e.g., raising, halt, liquidity impact) identified.*",
  "usage": {
    "prompt_tokens": 1707,
    "completion_tokens": 143,
    "total_tokens": 1850,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T23:14:47.012997"
}